期刊文献+

uNTX水平检测的临床意义 被引量:4

Clinical significance of urinary type Ⅰ collagen cross-linked N-telopeptides in bone metastases neoplasm
下载PDF
导出
摘要 目的 测定患者尿Ⅰ型胶原交联氨基末端肽(uNTX)水平,评价其与骨转移瘤病情发展和疗效的关系。方法 研究对象分为A、B、C三组。A组为正常成人组;B组为原发肿瘤组;C组为骨转移瘤组。分别检测3组uNTX水平及血清AKP活性和Ca^2+浓度。C组治疗后10~12周进行uNTX的随访观察。结果 C组uNTX水平显著高于A、B两组,骨转移瘤患者治疗前后uNTX水平也有显著性差异。结论 uNTX水平与骨转移的发生呈正相关,uNTX敏感性高于血清AKP活性和Ca^2+浓度,在鉴别骨转移瘤和监测病变进程中有预测价值,也是评价骨转移瘤患者疗效反应的早期客观指标之一。 Objective To analyze the significance of urinary typeⅠcollagen cross-linked N-telopeptides (uNTX) for the prognosis and response to therapy of bone metastatic neoplasms. Methods The subjects were divided into 3 groups: A, B and C. The levels of uNTX were measured by enzymatic immunoassay kit,and the activity of serum alkaline phosphatases(AKP) and calcium concentration were measured simuhanuously. Results uNTX levels positively correlated with bone metastatic neoplasms,and were markedly high in the patients with extensive bone collagen breakdown. Conclusions uNTX is more sensitive than the activity of serum AKP and plasma calcium concentration for bone metastasis of neoplasms, so it is significant in differentiating and monitoring bone metastatic neoplasms. The measurement of uNTX is an early objective methods for evaluation of prognostic response to therapy of bone metastatic neoplasms.
出处 《临床检验杂志》 CAS CSCD 北大核心 2007年第2期141-143,共3页 Chinese Journal of Clinical Laboratory Science
关键词 Ⅰ型胶原交联氨基末端肽 转移瘤 原发肿瘤 bone metastatic neoplasm urinary type Ⅰ collagen cross-linked N-telopeptides
  • 相关文献

参考文献7

  • 1Hanson DA,Eyre DR.Molecular site specificity of pyridinoline and pyrrole cross-links in type Ⅰ collagen of human bone[J].J Biol Chem,1996,271 (43):26508.
  • 2Apone S,Fevold K,Lee M,et al.A rapid method for quantifying osteoclast activity in vitro[J].J Bone Min Res,1994,9 (1):178.
  • 3Glover D,Lipton A,Keller A,et al.Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer[J].Cancer,1994,74 (11):2949-2955.
  • 4Woitge H W,Pecherstorfer M,Yuming L I,et al.Novel serum markers of bone resorption:clinical assessment and comparison with established urinary indices[J].J Bone Min Res,1999,14(5):792-801.
  • 5Clemens J D,Herricl M V,Singer F R,et al.Evidence that serum NTx (collagen-type Ⅰ N-telopeptides)can act as an immunochemical marker of bone resorption[J].Clin Chem,1997,43(11):2058.
  • 6严惟力,黄刚,袁济民.转移性骨肿瘤的骨损害标志物[J].国外医学(肿瘤学分册),2005,32(11):878-880. 被引量:3
  • 7Costa L,Demers Laurence M,Gouveia Oliveira A,et al.Prospective evaluation of the peptide-bound collagentype Ⅰ cross-links N-telopeptide and C-telopeptide in predicting bone metastases status[J].J Clin Oncol,2002,20 (3):850-856.

二级参考文献17

  • 1Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol, 2003,30(5 ) :616-634.
  • 2Stafford SE, Gralow JR, Schubert EK,et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol, 2002,9 (8) :913 921.
  • 3Martinetti A, Seregni E, Ripamonti C, et al. Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. Int J Biol Markers, 2002, 17 (4) :253-258.
  • 4Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res,2004,21 (2) :228-241.
  • 5Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer,2004,111(5) :783-791.
  • 6Jung K, Stephan C, Semjonow A,et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol,2003,170 (6pt1) :2302-2305.
  • 7Scher HI, Eisenberger M, D' Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen:recommendations from the ProstateSpecific Antigen Working Group. J Clin Oncol, 2004, 22(3 ):537-556.
  • 8Luftner D, Luke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem, 2003, 36 (4): 233-240.
  • 9Koizumi M, Yonese J, Fukui I, et al. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol, 2002, 167(4) :1863 1866.
  • 10Francini G, Petrioli R, Gonnelli S, et al. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer,2001, 92(6) :1468-1474.

共引文献2

同被引文献55

引证文献4

二级引证文献281

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部